Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL644462 | 0.78 | — | — | |
| SCHEMBL3541272 | 0.75 | HSD17B10 (0.31) | — | |
| SCHEMBL448720 | 0.75 | HSD17B10 (0.31) | — | |
| SCHEMBL644944 | 0.69 | RECQL (0.48) | MAPK1 | |
| SCHEMBL22440292 | 0.69 | CA12 (0.30) | — | |
| SCHEMBL22282962 | 0.69 | — | — | |
| SCHEMBL14582189 | 0.69 | RECQL (0.48) | MAPK1 | |
| SCHEMBL1164351 | 0.69 | ALDH1A1 (0.32) | — | |
| SCHEMBL2791591 | 0.68 | RECQL (0.47) | MAPK1 | |
| SCHEMBL8529790 | 0.67 | ALDH1A1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4244235-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TRANSFERRIN RECEPTOR 1 (TFR1) | BicycleTX Limited (GB) | 2023-09-20 | — | — | EP | claimed |
| EP-4003530-A1 | HETEROTANDEM BICYCLIC PEPTIDE COMPLEXES | BicycleTX Limited (GB) | 2022-06-01 | — | — | EP | claimed |
| WO-2022101633-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TRANSFERRIN RECEPTOR 1 (TfR1) | BICYCLETX LIMITED (GB) | 2022-05-19 | — | — | WO | claimed |
| WO-2025073871-A1 | BICYCLIC PEPTIDE LIGAND COMPLEXES SPECIFIC FOR TFR1 | BICYCLETX LIMITED (GB) | 2025-04-10 | — | — | WO | disclosed |
| WO-2025046146-A1 | POLYPEPTIDE SCREENING | Bicycle TX Limited (GB) | 2025-03-06 | — | — | WO | disclosed |
| WO-2024009108-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | BICYCLETX LIMITED (GB) | 2024-01-11 | — | — | WO | disclosed |
| US-11833211-B2 | Methods of suppression and treatment of disease comprising administering bicycle peptide ligands specific for EphA2 | BICYCLETX LIMITED (GB) | 2023-12-05 | — | — | US | disclosed |
| EP-4274840-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | BicycleTx Limited (GB) | 2023-11-15 | — | — | EP | disclosed |
| EP-4274839-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | BicycleTx Limited (GB) | 2023-11-15 | — | — | EP | disclosed |
| EP-4274843-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | BicycleTx Limited (GB) | 2023-11-15 | — | — | EP | disclosed |
| US-20230144799-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 | BICYCLETX LIMITED (GB) | 2023-05-11 | — | — | US | disclosed |
| EP-4153240-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4 AND USES THEREOF | BicycleTX Limited (GB) | 2023-03-29 | — | — | EP | disclosed |
| EP-4065085-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 AND USES THEREOF | BicycleTX Limited (GB) | 2022-10-05 | — | — | EP | disclosed |
| WO-2022148970-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | BICYCLETX LIMITED (GB) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022148968-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | BICYCLETX LIMITED (GB) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022148971-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | BICYCLETX LIMITED (GB) | 2022-07-14 | — | — | WO | disclosed |
| EP-3965827-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR OX40 | BicycleTX Limited (GB) | 2022-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11833211-B2 | Methods of suppression and treatment of disease comprising administering bicycle peptide ligands specific for EphA2 | EPHA2, EPHB2, EPHB1 | TRPA1 4681/4885MAPK1 2741/4885 |
| US-20230144799-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 | EPHA2, EPHB2, ERBB2 | TRPA1 4063/4885MAPK1 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.